Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.39 |
| ▸ | FDPS | P14324 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25950632 | 0.82 | CES2 (0.42) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL19736033 | 0.80 | CES2 (0.41) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL20203168 | 0.78 | CES2 (0.40) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL23894886 | 0.76 | CES2 (0.37) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL24916372 | 0.74 | MEN1 (0.37) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL1868965 | 0.74 | CES2 (0.47) | CES2GGPS1FDPS | |
| SCHEMBL8521468 | 0.73 | CES2 (0.42) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL19939441 | 0.73 | CES2 (0.42) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL23346658 | 0.73 | MEN1 (0.36) | CES2GGPS1FDPSMEN1MAPT | |
| SCHEMBL12477837 | 0.72 | GGPS1 (0.39) | CES2GGPS1FDPSLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | PPARG, PPARA, PPARD | CES2 3858/4885GGPS1 1385/4885FDPS 2264/4885 |
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | PPARG, PPARA, PPARD | CES2 3858/4885GGPS1 1385/4885FDPS 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.